NCT02366013View on ClinicalTrials.gov

Trial of the Safety and Immunogenicity of an Oral, Replicating Ad26 Vectored HIV-1 Vaccine

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

June 30, 2016

Study Completion Date

June 30, 2016

Conditions
HIV
Interventions
BIOLOGICAL

rcAd26.MOS1.HIV-Env 1x10^8 vp

1 oral capsule, 1x10\^8 vp/capsule or 1 placebo capsule; 5:1 vaccine:placebo

BIOLOGICAL

rcAd26.MOS1.HIV-Env 1x10^9 vp

10 oral capsules, 1x10\^8 vp/capsule or 10 placebo capsules; 5:1 vaccine:placebo

BIOLOGICAL

rcAd26.MOS1.HIV-Env 1x10^10 vp

1 oral capsule, 1x10\^10 vp/capsule or 1 placebo capsule; 5:1 vaccine:placebo

BIOLOGICAL

rcAd26.MOS1.HIV-Env 1x10^11 vp

10 oral capsules, 1x10\^10 vp/capsule or 10 placebo capsules; 5:1 vaccine:placebo

Trial Locations (1)

14642

University of Rochester, Rochester

All Listed Sponsors
collaborator

University of Rochester

OTHER

collaborator

Beth Israel Deaconess Medical Center

OTHER

lead

International AIDS Vaccine Initiative

NETWORK

NCT02366013 - Trial of the Safety and Immunogenicity of an Oral, Replicating Ad26 Vectored HIV-1 Vaccine | Biotech Hunter | Biotech Hunter